{"preliminary_commentary":{"by_channel":{"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tiragolumab","atezolizumab"]],"indication":"untreated extensive-stage small cell lung cancer","name":"SKYSCRAPER-02C","nct_id":"NCT04665856","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skyscraper-02c-nct04665856. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SKYSCRAPER-02C","arms":[{"description":"Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.","label":"Tiragolumab + Atezolizumab + Carboplatin and Etoposide","type":"EXPERIMENTAL"},{"description":"Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles","label":"Placebo + Atezolizumab + Carboplatin and Etoposide","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-11-17","type":"ACTUAL"},"conditions":["Small Cell Lung Carcinoma"],"enrollment":{"count":123,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tiragolumab","otherNames":["MTIG7192A"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Tiragolumab Matching Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-18","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)","timeFrame":"From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 32.3 months)"},{"measure":"Overall Survival (OS) in the PAS","timeFrame":"From randomization to death from any cause (up to approximately 32.3 months)"}],"references":[],"start_date":{"date":"2020-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04665856"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skyscraper-02c-nct04665856"}